The US Food and Drug Administration (FDA) has issued a complete response letter (CRL) for Alvotech鈥檚 Humira biosimilar AVT02, further delaying the company鈥檚 plans to launch the drug in a landmark year.
The agency the drug鈥檚 biologics licence application (BLA) over deficiencies seen at one of the company鈥檚 manufacturing facilities in Reykjavik, Iceland, according to Alvotech’s press release on 28 June.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataWhile the FDA did not make a note of any other deficiencies in the BLA, issues related to the Reykjavik facility need to be resolved to facilitate the drug鈥檚 potential approval.
This marks the second time that the FDA has rejected AVT02鈥檚 BLA this year. In April, the regulator issued a CRL to Alvotech, which also noted the deficiencies seen in the company鈥檚 Reykjavik plant. Prior to that, the company received a CRL from the FDA over deficiencies in the plant in September 2022.
Alvotech plans to resubmit the BLA, which will feature additional data aimed at securing an interchangeability designation. The resubmission would start another six-month review period.
Due to this, the company aims to explore options aimed at raising capital, which includes equity financing and the sale of convertible bonds. According to the announcement, Alvotech鈥檚 largest shareholder ATP Holdings has voiced its interest in offering up to $100m in proceeds from potential financing to the company.
AVT02 is a high-concentration biosimilar to Humira. Also known as adalimumab, Humira has long been regarded as one of the key blockbuster drugs on the market that made billions of dollars since its US launch in 2003.
Humira is indicated for multiple conditions that include Crohn鈥檚 disease and rheumatoid arthritis. It is a monoclonal antibody that serves as a tumour necrosis factor (TNF) blocker.
has long pursued an assertive legal strategy surrounding the drug and other companies had to negotiate for the earlier entry of their biosimilar to the US market.
While biosimilar Amjevita was approved by the FDA in September 2016, the company was not able to launch the product until January 2023. Indeed, although AVT02 is not approved in the US, the biosimilar has already been approved in Australia, Canada, and the EU.
More Humira biosimilars are set to reach the US market, including Cyltezo and Abrilada. Cyltezo will become available on 1 July, while Abrilada can launch as early as July.
The company is also developing a biosimilar to Janssen鈥檚 Stelara called AVT04. On 12 June, Alvotech and reached a settlement and licence agreement with , which fully owns Janssen. The settlement in the US for no later than 21 February 2025, as per the announcement.
In August 2020, Alvotech and Teva announced their strategic partnership to commercialise Alvotech’s biosimilars in the US.
